Phase Ib Study of Ribociclib plus Fulvestrant and Ribociclib plus Fulvestrant plus PI3K Inhibitor (Alpelisib or Buparlisib) for HR+ Advanced Breast Cancer
Sign Up to like & getrecommendations! Published in 2020 at "Clinical Cancer Research"
DOI: 10.1158/1078-0432.ccr-20-0645
Abstract: Purpose: Resistance to treatment with endocrine therapy in patients with HR+, HER2− advanced breast cancer (ABC) is common and dual inhibition of CDK4/6 and PI3K pathways may delay the development of resistance. This phase Ib… read more here.
Keywords: ribociclib; ribociclib plus; cancer; fulvestrant ribociclib ... See more keywords
Is adding ribociclib to fulvestrant cost-effective in treating postmenopausal women with HR+/HER2- advanced or metastatic breast cancer? A US payer perspective cost utility analysis.
Sign Up to like & getrecommendations! Published in 2022 at "Journal of managed care & specialty pharmacy"
DOI: 10.18553/jmcp.2022.28.11.1282
Abstract: BACKGROUND: Breast cancer is the most prevalent type of cancer in women in the United States. Ribociclib plus fulvestrant combination therapy gained US Food and Drug Administration approval to treat postmenopausal women with hormone receptor-positive/human… read more here.
Keywords: breast cancer; cost; plus fulvestrant; ribociclib plus ... See more keywords